Results 81 to 90 of about 58,504 (176)

Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump.: Sorafenib inhibits ABCG2 and overcome irinotecan resistance.

, 2013
International audienceDespite recent advances in the treatment of colorectal cancer (CRC), tumor resistance is a frequent cause of chemotherapy failure.
Leconet, Wilhem, Jarlier, Marta, Evrard, Alexandre, Martineau, Pierre, Mazard, Thibault, Vezzio-Vie, Nadia, Torro, Adeline, del Rio, Maguy, Gongora, Celine, Causse, Annick, Ychou, Marc, Assenat, Eric, Simony, Joelle, Robert, Bruno   +13 more
core   +1 more source

Ramucirumab plus FOLFIRI or irinotecan as second-line treatment for patients with gastroesophageal adenocarcinoma: a review and meta-analysis of an emerging option

Frontiers in Oncology
IntroductionThe aim of this study was to provide a review of the clinical evidence for use of ramucirumab (RAM) plus folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan (FOLFIRI) or irinotecan as second-line treatment in gastroesophageal ...
Haeseong Park, Samuel J. Klempner, Joseph Chao, Zev A. Wainberg, Mariusz Lukanowski, Suresh Chenji, Shannon Bourke, Anindya Chatterjee, Sylvie Lorenzen   +8 more
doaj   +1 more source

Cellular irinotecan resistance in colorectal cancer and overcoming irinotecan refractoriness through various combination trials including DNA methyltransferase inhibitors: a review

, 2021
Treatment with pharmacological drugs for colorectal cancer (CRC) remains unsatisfactory. A major cause of failure in pharmacotherapy is the resistance of colon cancer cells to the drugs, creating an urgent issue.
Habano, Wataru, Ozawa, Shogo, Miura, Toshitaka, Terashima, Jun   +3 more
core  

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology
Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge. We previously showed that camptothecin induces ubiquitin–proteasome pathway (UPP)‐mediated topoI degradation.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
doaj   +1 more source

Response of small intestinal epithelial cells to irinotecan.

, 2013
(A) Significant decrease in the number of BrdU postive cells in the small intestinal crypts of irinotecan-treated mice. WT mice were injected with PBS (cont) or irinotecan (CPT) for 6 consecutive days and sacrificed on day 7. One hour prior to sacrifice,
Helen Piwnica-Worms (251639), Lynn S. White (357111), Sofia Origanti (357109), Gwanghee Lee (271155), Thaddeus S. Stappenbeck (357117), Jinwu Sun (357114)   +5 more
core   +1 more source

Protective effects of N-acetylcysteine against irinotecan – induced pulmonary toxicity in female albino rats

Zanco Journal of Medical Sciences
Background and objective: Idiopathic pulmonary fibrosis (IPF) is a deadly lung illness characterized by progressive lung fibrosis and deteriorating lung function, with the uncertain origin and few therapeutic options. Chemotherapy such as Irinotecan (IRI)
Hawrin Burhan Khudhur, Ansam Al-Hassani
doaj   +1 more source

Irinotecan-induced diarrhea:functional significance of the polymorphic ABCC2 transporter protein

, 2007
Interindividual pharmacokinetic variability of the anticancer agent irinotecan is high. Life-threatening diarrhea is observed in up to 25% of patients receiving irinotecan and has been related with irinotecan pharmacokinetics and UGT1A1 genotype status ...
McLeod, HL, de Jong, FA (Floris), Kroetz, DL, Verweij, Jaap, Friberg, Lena E.,, de Jong, F. A., Marsh, S, McLeod, H. L., Mathijssen, R. H., Kroetz, D. L., Verweij, J., Sparreboom, A., Scott-Horton, TJ, Sparreboom, A, Marsh, S., Mathijssen, RH; id_orcid, Friberg, LE, Scott-Horton, T. J.   +17 more
core   +1 more source

Reactivation of hepatitis B after irinotecan

, 2004
Objective: To analyse the incidence of hepatitis B reactivation following treatment with irinotecan-based combined chemotherapy and the outcomes of patients with hepatitis B reactivation.
Kwok, CCH, Lui, LCY, Yau, CC, Wong, WM, Lai, CL, Au, GKH, Chan, RTT   +6 more
core  

Maritoclax Overcomes FBW7 Deficiency‐Driven Irinotecan Resistance in Colorectal Cancer by Targeting MCL1

Cancer Medicine
Introduction FBW7, a tumor suppressive E3 ubiquitin ligase frequently mutated in colorectal cancer (CRC), mediates chemotherapy resistance. While irinotecan (via its active metabolite SN38) is a first‐line TOP1 inhibitor for advanced CRC, the mechanistic
Qian Lin, Shuting Liu, Hongfei Jiang, Shasha Wang, Yixin Duan   +4 more
doaj   +1 more source

Complete response of a metastatic gastroesophageal adenocarcinoma on irinotecan-based chemotherapy in a dialysis patient

, 2010
J Verwimp1, F Geurs1, S Ponette2, J Ponette2, J Martens3, K Bulté21Department of Medical Oncology, 2Department of Gastroenterology, 3Department of Nephrology, Regionaal Ziekenhuis Sint-Maria, Ziekenhuislaan, Halle, BelgiumAbstract: We present ...
et al, F Geurs, S Ponette, J Verwimp
core